Search results
Actionable Investing Lists. Find the latest stock market trends and activity today. Compare key indexes, including Nasdaq Composite, Nasdaq-100, Dow Jones Industrial & more.
Aug 25, 2022 · Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25 after the close of trading on the Nasdaq Stock Market on Friday, August 26, 2022. Athersys common stock will begin trading on a split ...
3 days ago · October 10, 2023 | marketbeat.com. Trading was temporarily halted for "ATHX" at 08:10 AM with a stated reason of "News pending." October 3, 2023 | businesswire.com. Athersys Licenses its Animal Health Assets to Ardent Animal Health. October 2, 2023 | finance.yahoo.com.
Apr 18, 2022 · Athersys advised in its 2021 10-K (p. 41), it has drawn on this periodically in recent years as follows: 2019 - sold 14,475,000 shares at an average price of $1.41; 2020 - sold 11,425,000 shares ...
Oct 17, 2023 · Presumably that means there won’t be any meme stock activity given that those players seem to only like the truly hopeless cases. Athersys (NASDAQ: ATHX) stock is up 40% this morning premarket. This is after that warning of possible bankruptcy rather hit the ATHX stock price. This is not, though, like the varied foolishness we have seen with ...
The price was around 3. Today we sit at 195 million and a price of .84. Lack of management delivering on what they say they will. Subsequently they are not believed. I am at a complete loss when trying to understand what is going on with this company’s stock price.
1 day ago · Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform ...
